VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification.

TRIAL DESIGN to further validate the FORTA (Fit fOR The Aged) concept, a bicentric randomised, controlled trial was run in two geriatric clinics. METHODS patients (≥65 years, ≥3 drugs or ≥60 years, ≥6 drugs) with three relevant diseases and hospitalisation for ≥5 days were randomised. In the intervention, but not the control group, a FORTA team instructed ward physicians on FORTA. FORTA is the first positive/negative listing approach labelling medications used to treat chronic illnesses in older patients from A (indispensable), B (beneficial), C (questionable) to D (avoid). The primary end point was the FORTA score: sum of medication errors classified as over-, under- and mistreatment. Consecutive patients were randomised to the intervention and control ward; outcome assessment was blinded. RESULTS four hundred and nine patients (age 81.5 years, 64% female, hospitalisation 17.4 days) were included. The primary end point was significantly (P < 0.0001) more reduced in the intervention versus control groups (2.7 ± 2.25 versus 1 ± 1.8, mean ± SD, intergroup comparison of admission/discharge differences). Over- and under-treatment scores and use of A (increase) and D (decrease) drugs were significantly improved (P < 0.01). The total number of adverse drug reactions (ADRs) was significantly reduced by FORTA (P < 0.05, number needed to treat is 5). Activities of daily living and renal failure improved significantly (P < 0.05). Blood pressure remained constant in the intervention, but decreased significantly in the control group. CONCLUSION applying FORTA to hospitalised geriatric patients leads to improvement of medication quality and may improve secondary clinical end points (e.g. ADRs). The concept is amenable to successful communication and implementation. Registration (DRKS-ID): DRKS00000531. FUNDING DFG-German Research Foundation (WE 1184/15-1).

[1]  M. Wehling How to Use the FORTA (“Fit fOR The Aged”) List to Improve Pharmacotherapy in the Elderly , 2015, Drug Research.

[2]  G. Onder,et al.  Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. , 2014, Age and ageing.

[3]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[4]  M. Wehling,et al.  Effects of “Fit fOR The Aged” (FORTA) on pharmacotherapy and clinical endpoints—a pilot randomized controlled study , 2014, European Journal of Clinical Pharmacology.

[5]  C. Weiss,et al.  Consensus Validation of the FORTA (Fit fOR The Aged) List: A Clinical Tool for Increasing the Appropriateness of Pharmacotherapy in the Elderly , 2013, Drugs & Aging.

[6]  Paul J Nietert,et al.  The Prevalence of Chronic Diseases and Multimorbidity in Primary Care Practice: A PPRNet Report , 2013, The Journal of the American Board of Family Medicine.

[7]  C. Campanelli American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012 .

[8]  H. Frohnhofen,et al.  Bewertung von Medikamenten in der Geriatrie mit der neuen FORTA-Klassifikation , 2011, Deutsche medizinische Wochenschrift.

[9]  P. Gallagher,et al.  Prevention of Potentially Inappropriate Prescribing for Elderly Patients: A Randomized Controlled Trial Using STOPP/START Criteria , 2011, Clinical pharmacology and therapeutics.

[10]  Martin Wehling,et al.  GUIDELINE‐DRIVEN POLYPHARMACY IN ELDERLY, MULTIMORBID PATIENTS IS BASICALLY FLAWED: THERE ARE ALMOST NO GUIDELINES FOR THESE PATIENTS , 2011, Journal of the American Geriatrics Society.

[11]  Sven Schmiedl,et al.  Potentially inappropriate medications in the elderly: the PRISCUS list. , 2010, Deutsches Arzteblatt international.

[12]  D. Light 1. Bearing the Risks of Prescription Drugs , 2010 .

[13]  M. Wehling MULTIMORBIDITY AND POLYPHARMACY: HOW TO REDUCE THE HARMFUL DRUG LOAD AND YET ADD NEEDED DRUGS IN THE ELDERLY? PROPOSAL OF A NEW DRUG CLASSIFICATION: FIT FOR THE AGED , 2009, Journal of the American Geriatrics Society.

[14]  M. Wehling,et al.  [Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA]. , 2008, Deutsche medizinische Wochenschrift.

[15]  P. Gallagher,et al.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. , 2008, International journal of clinical pharmacology and therapeutics.

[16]  R. Page,et al.  The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. , 2006, The American journal of geriatric pharmacotherapy.

[17]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[18]  Claudio Pedone,et al.  Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. , 2005, Archives of internal medicine.

[19]  J. Gurwitz Polypharmacy: a new paradigm for quality drug therapy in the elderly? , 2004, Archives of internal medicine.

[20]  R. Bressler,et al.  Principles of drug therapy for the elderly patient. , 2003, Mayo Clinic proceedings.

[21]  Stephen H. D. Jackson,et al.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.

[22]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[23]  J A Knottnerus,et al.  Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. , 1998, Journal of clinical epidemiology.